Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models

Vu H. Duong; Jeffrey E. Lancet; Ezzideen Alrawi; Najla H. Al-Ali; Janelle Perkins; Teresa Field; Pearlie K. Epling-Burnette; Ling Zhang; Alan F. List; Rami S. Komrokji

doi:10.1016/j.leukres.2012.12.012

Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models

Vu H. Duong, Jeffrey E. Lancet, Ezzideen Alrawi, Najla H. Al-Ali, Janelle Perkins, Teresa Field, Pearlie K. Epling-Burnette, Ling Zhang, Alan F. List, Rami S. Komrokji

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Azacitidine's efficacy in therapy-related myeloid neoplasms (t-MN) has not been well-studied. In our retrospective review of 84 t-MN patients treated with azacitidine, median overall survival (OS) was 14.5 months and overall response rate was 43%, including 11% complete remission, 4% marrow complete remission, and 11% partial remission. In patients who underwent allogeneic transplant (25%), median OS was 19.2 versus 12.8 months (P= 0.023) for those who did not. Response rates were comparable to those reported for de novo myelodysplastic syndrome. When we analyzed outcomes according to five scoring systems, only the Global MD Anderson Risk Model predicted survival with statistical significance.

Original language	English (US)
Pages (from-to)	510-515
Number of pages	6
Journal	Leukemia research
Volume	37
Issue number	5
DOIs	https://doi.org/10.1016/j.leukres.2012.12.012
State	Published - May 2013
Externally published	Yes

Bibliographical note

Funding Information:
RSK was on the Speaker's Bureau and had research funding from Celgene. JEL was a Consultant (Celgene) and received grant funding to institution for efforts from Celgene. AFL was a Consultant and received research funding from Celgene.

Keywords

Azacitidine
Myelodysplastic syndrome
Therapy-related myelodysplastic syndrome
Therapy-related myeloid neoplasms

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.leukres.2012.12.012

OpenUrl availability

Full text

Cite this

Duong, V. H., Lancet, J. E., Alrawi, E., Al-Ali, N. H., Perkins, J., Field, T., Epling-Burnette, P. K., Zhang, L., List, A. F., & Komrokji, R. S. (2013). Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models. Leukemia research, 37(5), 510-515. https://doi.org/10.1016/j.leukres.2012.12.012

@article{b79097d5170345a3985b839e89ee2dc3,

title = "Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models",

abstract = "Azacitidine's efficacy in therapy-related myeloid neoplasms (t-MN) has not been well-studied. In our retrospective review of 84 t-MN patients treated with azacitidine, median overall survival (OS) was 14.5 months and overall response rate was 43%, including 11% complete remission, 4% marrow complete remission, and 11% partial remission. In patients who underwent allogeneic transplant (25%), median OS was 19.2 versus 12.8 months (P= 0.023) for those who did not. Response rates were comparable to those reported for de novo myelodysplastic syndrome. When we analyzed outcomes according to five scoring systems, only the Global MD Anderson Risk Model predicted survival with statistical significance.",

keywords = "Azacitidine, Myelodysplastic syndrome, Therapy-related myelodysplastic syndrome, Therapy-related myeloid neoplasms",

author = "Duong, {Vu H.} and Lancet, {Jeffrey E.} and Ezzideen Alrawi and Al-Ali, {Najla H.} and Janelle Perkins and Teresa Field and Epling-Burnette, {Pearlie K.} and Ling Zhang and List, {Alan F.} and Komrokji, {Rami S.}",

note = "Funding Information: RSK was on the Speaker's Bureau and had research funding from Celgene. JEL was a Consultant (Celgene) and received grant funding to institution for efforts from Celgene. AFL was a Consultant and received research funding from Celgene. ",

year = "2013",

month = may,

doi = "10.1016/j.leukres.2012.12.012",

language = "English (US)",

volume = "37",

pages = "510--515",

journal = "Leukemia research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "5",

}

TY - JOUR

T1 - Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models

AU - Duong, Vu H.

AU - Lancet, Jeffrey E.

AU - Alrawi, Ezzideen

AU - Al-Ali, Najla H.

AU - Perkins, Janelle

AU - Field, Teresa

AU - Epling-Burnette, Pearlie K.

AU - Zhang, Ling

AU - List, Alan F.

AU - Komrokji, Rami S.

N1 - Funding Information: RSK was on the Speaker's Bureau and had research funding from Celgene. JEL was a Consultant (Celgene) and received grant funding to institution for efforts from Celgene. AFL was a Consultant and received research funding from Celgene.

PY - 2013/5

Y1 - 2013/5

N2 - Azacitidine's efficacy in therapy-related myeloid neoplasms (t-MN) has not been well-studied. In our retrospective review of 84 t-MN patients treated with azacitidine, median overall survival (OS) was 14.5 months and overall response rate was 43%, including 11% complete remission, 4% marrow complete remission, and 11% partial remission. In patients who underwent allogeneic transplant (25%), median OS was 19.2 versus 12.8 months (P= 0.023) for those who did not. Response rates were comparable to those reported for de novo myelodysplastic syndrome. When we analyzed outcomes according to five scoring systems, only the Global MD Anderson Risk Model predicted survival with statistical significance.

AB - Azacitidine's efficacy in therapy-related myeloid neoplasms (t-MN) has not been well-studied. In our retrospective review of 84 t-MN patients treated with azacitidine, median overall survival (OS) was 14.5 months and overall response rate was 43%, including 11% complete remission, 4% marrow complete remission, and 11% partial remission. In patients who underwent allogeneic transplant (25%), median OS was 19.2 versus 12.8 months (P= 0.023) for those who did not. Response rates were comparable to those reported for de novo myelodysplastic syndrome. When we analyzed outcomes according to five scoring systems, only the Global MD Anderson Risk Model predicted survival with statistical significance.

KW - Azacitidine

KW - Myelodysplastic syndrome

KW - Therapy-related myelodysplastic syndrome

KW - Therapy-related myeloid neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84875892583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875892583&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2012.12.012

DO - 10.1016/j.leukres.2012.12.012

M3 - Article

C2 - 23332452

AN - SCOPUS:84875892583

SN - 0145-2126

VL - 37

SP - 510

EP - 515

JO - Leukemia research

JF - Leukemia research

IS - 5

ER -

Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this